Investment
Features
FeesSafety
Academy
More
Pluang+

WHO recommends Regeneron's Ebola antibody maftivimab for trials against Bundibugyo outbreak

Market News
28 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Regeneron's antibody maftivimab, part of the FDA-approved Ebola treatment Inmazeb, has been recommended by WHO for clinical trials targeting the current Bundibugyo ebolavirus outbreak in the DRC and Uganda. Maftivimab has shown broad lab activity against multiple Ebola strains, including Bundibugyo, though it hasn't been tested alone in patients for this strain. The WHO is collaborating with affected countries to facilitate trials, with Regeneron coordinating closely with U.S. health authorities and providing existing drug supplies for immediate use or study. This move aims to develop effective treatments amid the public health emergency declared by WHO for the outbreak.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App